Document is current
Any future updates will be listed below
-
Authors
El Abd, Asmae
Dasari, Harika
Dodin, Philippe
Trottier, Helen
Ducharme, Francine M.
-
Funding
Funding for this research was provided by:
Fonds de Recherche du Québec - Santé (333208)
Canadian Institutes of Health Research (153252, 153252)
CHU Sainte-Justine Foundation
- License Information
-
More Information
Article History
Received: 30 April 2024
Accepted: 3 September 2024
First Online: 19 September 2024
Declarations
:
: Not applicable.
: Not applicable.
: FMD has received unrestricted research funds from Jamieson and GSK, as well as investigator-initiated research funds from Covis Pharma, the Banque Scotia Foundation, GlaxoSmithKline, and MEDteq in partnership with Thorasys, Inc. FMD has received an honorarium for consultancy work from INESSS, Astra Zeneca, Covis Pharma, Ontario Lung Association, Sanofi, and Teva. FMD has also been on the advisory board for Sanofi and has received honoraria as an invited speaker from the Association des Médecins omnipraticiens du Richelieu Saint-Laurent, Covis Pharma, Réseau québécois d’éducation en santé respiratoire (RQESR), Sanofi-Regeneron, Thorasys Inc., and Trudell Medical International. HT reported receiving occasional lecture fees from Merck and unrestricted grants from ViiV Healthcare. All the other co-authors declare that they have no competing interests.
